Patient experiences and preferences for IV versus subcutaneous immunotherapy in non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center observational survey enrolls adult patients with confirmed non-small cell lung cancer who have already received at least one cycle of an immune checkpoint inhibitor (atezolizumab, cemiplimab, durvalumab, nivolumab, or pembrolizumab). Participants complete questionnaires about satisfaction with IV infusions, perceived safety, convenience, and comfort, and about their preference for IV versus subcutaneous (SC) administration and location (hospital vs home). No experimental treatments are given; the study only collects patient-reported experiences and preferences. Results will be used to inform care delivery options and patient-centered administration strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* Age ≥ 18 years.
* \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
* \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
* \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion Criteria:

* \* Patients is unable to consent for themselves
* \* Patient has not yet completed the 1st cycle of ICI-based therapy

Where it's running

• Los Angeles General Medical Center
  Los Angeles, California, United States Recruiting
• USC / Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Robert Hsu — University of Southern California

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Atezolizumab after surgery to prevent NSCLC from coming back

  This trial tests whether giving atezolizumab (with or without hyaluronidase) for one year after complete surgery helps prevent NSCLC from returning compared with observation.

  Recruiting at 145 sites Phase 3 National Cancer Institute (NCI) · Anaheim, California and 144 other locations · NCT07388524

• Telisotuzumab vedotin combined with osimertinib for progressive, incurable non-small cell lung cancer

  This trial tests whether adding the antibody-drug telisotuzumab vedotin to ongoing osimertinib can shrink tumors or slow growth in adults with progressive, incurable non-small cell lung cancer who have EGFR mutations.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07323641

• Targeted post-surgery radiation plus standard therapy for NSCLC with remaining nodal cancer

  This phase II trial tests whether adding intensity-modulated post-operative radiation therapy to standard chemotherapy or immunotherapy helps people with non-small cell lung cancer and remaining lymph node cancer after surgery.

  Recruiting at 121 sites Phase 2 Alliance for Clinical Trials in Oncology · Jonesboro, Arkansas and 124 other locations · NCT07293247

• Using blood and tissue biomarkers to guide immunotherapy and later treatment choices in advanced non-small cell lung cancer

  This trial tests whether blood and tumor biomarkers can predict who will respond to first-line PD‑1/PD‑L1 immunotherapy and help pick better second-line treatments for people with stage IIIB–IV non‑small cell lung cancer.

  Recruiting at 13 sites Phase 2 City of Hope Medical Center · Goodyear, Arizona and 12 other locations · NCT07288034

• Psilocybin-assisted therapy for major depression in people with non-small cell lung cancer

  This phase II trial tests whether a single oral dose of psilocybin combined with psychotherapy can reduce moderate-to-severe depression in adults with non-small cell lung cancer.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07216404

• How past alcohol or drug use affects detection and treatment of non-small cell lung cancer

  This project will talk with adults who have non-small cell lung cancer and a history of alcohol or drug use to see if those histories help or hinder getting detected and treated.

  Recruiting at 2 sites University of Southern California · Los Angeles, California and 1 other locations · NCT07186699

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.